NOVATO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), today announced that the first patient has been dosed in the pivotal Phase 3 Aspire study (NCT06617429) ...

According to the latest BCC Research study on "Point-of-Care Diagnostics: Technologies and Global Markets," the POC market is ...

GE Vernova bounced off its 50-day line, offering a buying opportunity. Thursday's IBD Stock Of The Day is already up 130% ...

These providers enable healthcare organizations to adopt AI solutions more effectively by offering end-to-end support, from ...

Over the course of the projection period, sales of transformer tap changers and voltage control relays are expected to grow ...

Sara Cerruti of ServiceMax explores how gas turbine suppliers who integrate a Service Bill of Materials (sBOM) as part of a ...

It helps with trading in the energy market by analyzing trends, supports sustainability by lowering carbon emissions, and can be used for data streaming. It improves disaster resilience as it can ...

Earlier this year, Ultragenyx reached agreement with the Agency that CSF HS can be used as a surrogate endpoint for accelerated approval based on the body of data presented by the company ... and ...